Since the DEA first signaled that COVID-era telehealth flexibilities couldn't last forever, the "Special Registration" has been the industry's anticipated replacement: a permanent, purpose-built regulatory pathway allowing qualified telehealth practitioners to prescribe controlled substances without an initial in-person visit. The concept has been proposed, revised, commented on, and delayed — but never finalized.
What the Special Registration Would Do
The proposed Special Registration for Telemedicine (SRT) would create a new DEA registration category specifically for telehealth prescribers of controlled substances. Key provisions from the most recent proposed rule:
- Eligibility: Licensed practitioners with a standard DEA registration could apply for additional SRT authorization. The practitioner would need to meet state licensure requirements in the patient's state and comply with all other federal and state prescribing regulations.
- Initial consultation via telemedicine: The SRT would allow the first prescribing encounter to occur via audio-video telemedicine — without requiring a prior in-person visit. This is the critical provision that preserves the current telehealth TRT model.
- Prescribing limits: Some proposed versions included quantity limits or duration limits for controlled substance prescriptions issued under SRT authority. The specifics varied between proposal drafts.
- Recordkeeping: Enhanced documentation requirements beyond standard DEA prescribing records, including verification of patient identity and location.
Where It Stands (Mid-2026)
The regulatory timeline has been frustratingly slow:
| Date | Action |
|---|---|
| March 2023 | DEA published proposed rules for telemedicine prescribing of controlled substances |
| May 2023 | Public comment period closed with over 38,000 comments |
| Nov 2023 | DEA issued a second temporary extension of COVID flexibilities |
| 2024 | No final rule published; flexibilities extended again |
| 2025 | Revised proposed rule elements leaked but no formal publication |
| Mid-2026 | Final rule still pending; current flexibilities expire Dec 31, 2026 |
The volume of public comments (38,000+) and the complexity of balancing controlled substance safety with telehealth access have contributed to the delay. The DEA is navigating pressure from patient advocacy groups (who want maximum telehealth access), law enforcement (who want diversion controls), medical boards (who want clinical standards), and the telehealth industry (who want business continuity).
What Patients Should Understand
The SRT Would Be Good for TRT Patients
If finalized as proposed, the Special Registration preserves telehealth TRT access while adding regulatory structure. Your platform would need SRT authorization (an administrative step), but your patient experience — video consultations, labs at local facilities, medication shipped to your door — would remain essentially unchanged.
Implementation Will Take Time
Even if the final rule is published tomorrow, implementation requires a registration period for practitioners, guidance documents from the DEA, state-level regulatory alignment, and platform compliance buildout. A reasonable estimate: 6–12 months from final rule publication to full operational implementation.
The Transition Period Matters
Any final rule will almost certainly include transition provisions — a period during which existing telehealth prescribing relationships continue under current rules while practitioners obtain SRT authorization. This transition period protects patients from gaps in access.
The practical takeaway: The Special Registration is likely to happen eventually, preserving telehealth TRT access for most patients. But the timing is uncertain, and waiting for it to be finalized before planning your contingency is risky. Prepare as if the waiver might lapse, and treat the SRT as a favorable outcome that may take time to materialize.
The Bottom Line
Coming — Eventually
The DEA's Special Registration for telemedicine is the most likely permanent solution for telehealth controlled substance prescribing. It would preserve TRT access while adding regulatory structure. But "likely" isn't "certain," and "eventually" isn't "before December 31." Plan for the waiver to lapse, hope for the SRT to be finalized, and ensure your prescriber relationship is well-documented regardless.